NLS Collaboration

EIT Health Scandinavia has presented a hub that connects researchers, clinicians and industry with European biobanks and health data registries. The platform, EIT Health Biobanks and Health Data Registries, provides easy access to and exchange of information on European biobanks and health data registries which are crucial for promoting medical research and innovation, states EIT […]

In the beginning of March, Sahlgrenska Science Park, GoCo Health Innovation City, AstraZeneca, and other members of Health Innovation West invited participants, students, researchers, tech enthusiasts, life science experts, entrepreneurs, and others to a femtech innovation hackathon, a hackaton focused on reducing the gender health gap and advancing women’s health. Initiators of the hackaton were […]

The two companies have entered into an agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease. “I […]

At the Ordinary General Meeting Thursday 11th of April three new life science profiles were elected to Medicon Valley Alliance’s (MVA’s) Board of Directors. The new board members are Maria Björkqvist, Dean, Faculty of Medicine, Lund University, Professor, Research group leader Brain Disease biomarker Unit, Julia Davies, Professor of Oral Biology at Malmö University, Professor […]

The Novo Nordisk Foundation has awarded a grant of DKK 150 million to establish the Copenhagen Center for Biomedical Quantum Sensing. The centre aims to develop novel quantum sensing principles and techniques for early detection of diseases. It will be located with the Niels Bohr Institute, the physics department at Copenhagen Science City-partner University of […]

BioInvent International has announced a clinical trial collaboration and supply agreement with MSD International Business for a Phase 1/2a study of its monoclonal antibody BI-1910 in combination with KEYTRUDA. Under the terms of the supply agreement, MSD will provide its anti-PD-1 therapy KEYTRUDA to be used in combination with BI-1910. The Phase 1/2a trial will […]